GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Autolus Therapeutics reported AUCATZYL net product revenue of $41.2 million for Q3 2026, a 95% increase year-over-year.
The company raised its full-year 2026 AUCATZYL revenue guidance to at or above $150 million.
Gross margin improved to 57% driven by higher volumes and manufacturing efficiency initiatives.
Clinical programs for obe-cel are progressing with ongoing enrollment in lupus nephritis, pediatric ALL, and progressive multiple sclerosis.
FDA granted regenerative medicine advanced therapy (RMAT) designation for obe-cel in SLE and lupus nephritis on September 9, 2026.
Initial clinical data for the ALARIC trial in light-chain amyloidosis is expected at ASH in December 2026.
The company expects cash and equivalents to fund operations through Q2 2028 based on current plans and a $100 million credit facility tranche.
Net loss for the quarter was $55.1 million, an improvement from $79.1 million in the same period last year.
Research and development expenses increased to $30.9 million due to higher clinical manufacturing supply costs.
Selling, general, and administrative expenses decreased to $35.9 million primarily from reduced employment costs and professional fees.
Cash, cash equivalents, and marketable securities totaled $248.4 million as of September 30, 2026.
A conference call to discuss results is scheduled for November 10, 2026, at 8:30 am EST.

Company: Autolus Inc.
Keywords: Nasdaq:AUTL, Autolus Inc., AUTL, AUCATZYL, obe-cel, Dr Christian Itin